Malvern

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years who have mild to severe Alzheimers Disease AD with moderate to severe psychosis related to AD. This Phase 3 study aims to compare KarXT with a placebo to see how well it works in treating psychosis symptoms associated with AD, focusing on changes in hallucinations and delusions. Participants will receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind setup. The treatment period lasts up to 14 weeks, during which participants take the assigned capsules daily. The study design includes two groups running in parallel, with neither participants nor researchers knowing who receives the drug or placebo. During the study, participants will undergo assessments including the Neuropsychiatric Inventory-Clinician NPI-C focusing on hallucinations and delusions, Clinical Global Impressions-Severity scale, and other related scales to measure psychosis symptoms and caregiver distress. Safety and efficacy will be monitored throughout, with evaluations at baseline and at the end of treatment. The entire participation period extends up to 14 weeks.

This research aims to better understand mental health treatments for conditions like depression, OCD, and anxiety depression by analyzing existing patient data from Greenbrook. It focuses on how treatments are used and their effects, using information collected during routine clinical care. The study is observational and retrospective, looking back at past data rather than testing new treatments directly. The analysis includes patients treated with NeuroStar TMS, a non-invasive brain stimulation device, and those treated with Esketamine nasal spray for depression. These treatments are part of the collected data, and the study evaluates their use and outcomes over time without administering any new interventions. Participants data from 2011 onwards will be reviewed to assess changes in clinical outcome scores from before treatment to eight weeks after treatment. Researchers will monitor how these treatments impacted symptoms using recorded clinical scores. The study spans from May 2025 until December 2035, focusing on data already collected during routine care without requiring new visits or treatments from participants.

Researchers are evaluating real-world data to better understand how patient characteristics, symptoms, and treatment parameters affect clinical outcomes with the NeuroStar Transcranial Magnetic Stimulation TMS device. This observational study focuses on patients with depression, obsessive-compulsive disorder, and anxiety depression who have been treated with NeuroStar Advanced TMS Therapy System. The study aims to analyze changes in clinical assessment scores over an 8-week treatment period. The study involves patients who have received treatment with the NeuroStar Advanced TMS Therapy System, a non-invasive brain stimulation device. Data from treatments starting November 1, 2008, onwards will be reviewed retrospectively to explore how factors like age at baseline relate to changes in clinical scores after treatment. The study does not involve new interventions but evaluates existing medical records and treatment outcomes. Participants involvement includes the collection and analysis of their treatment and clinical outcome data over an 8-week period post-treatment. Researchers will assess changes in clinical assessment scores from baseline to post-treatment and correlate these with age and other factors. The study will continue until December 2035, with no direct procedures or interventions required from participants during the study period.